In addition, since very recent data documented the success of phase II clinical trials with ATX/LPA blockers in patients with idiopathic pulmonary fibrosis (IPF) [12,13], the aim of the review is also to explore how LPA is worth considering as a molecular target for anticancer therapies or even for adjuvant therapies. The gene discussed is ENPP2; the disease is idiopathic pulmonary fibrosis.